Int'l App. No.: PCT/US99/26746
Int'l Filing Date: 12 November 1999

REMARKS

The above-identified application is being entered into the National Phase from PCT application no. PCT/US99/26746.

Applicants have amended the claims to put them in conformity with U.S. practice. Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned **"Version with markings to show changes made."**

No new matter has been introduced.

Respectfully submitted,



Yuriy P. Stercho, Ph.D.
Attorney for Applicants
Registration No. 33,797

SMITHKLINE BEECHAM CORPORATION
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5018
Facsimile (610) 270-5073
n\yps\response\P32185\preamend

Int'l App. No.: PCT/US99/26746
Int'l Filing Date: 12 November 1999

"VERSION WITH MARKING TO SHOW CHANGES MADE"

In the specification:

An abstract has been added.

In the claims:

3. (Amended) A method according to [claim 1 or] claim 2, wherein the Threshold Plasma Concentration is within the range of from about 50 to about 120ng/mL or about 60 to about 120ng/mL or about 90 to about 110ng/mL or about 95 to about 105ng/mL.

4. (Amended) A method according to [any one of] claim[s] 1 [to 3], wherein a minimum value of the Threshold Plasma Concentration (or the Minimum Threshold Plasma Concentration) of the insulin sensitiser is its SC50 concentration.

5. (Amended) A method according to [any one of] claim [1 to] 4, wherein a Preferred Threshold Plasma Concentration for the insulin sensitiser is twice the SC50 concentration.

6. (Amended) A method according to [any one of] claim 1 [to 5], wherein the plasma concentration of the insulin sensitiser remains substantially within the range from the Minimum Threshold Plasma Concentration to a level at or above the Preferred Threshold Plasma Concentration.

8. (Amended) A method according to [any one of] claim[s 4 to 6] 7, wherein the insulin sensitiser is Compound (I) and the SC50 is within the range of 40 to 65 ng/mL.

10. (Amended) A method according to [any one of] claim[s 6 to 9] 7 wherein the insulin sensitiser is Compound (I) and the Preferred Threshold Plasma Concentration is in the range of about 80 to about 130 ng/mL or about 82.2 to about 123.4ng/mL.

15. (Amended A method according to any one of claims 1 to 6, wherein the insulin sensitiser is

Int'l App. No.: PCT/US99/26746
Int'l Filing Date: 12 November 1999

selected from the group consisting of 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (or troglitazone), 5-[4-[(1-methylcyclohexyl)methoxy]benzyl] thiazolidine-2,4-dione (or ciglitazone), 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl] thiazolidine-2,4-dione (or pioglitazone) [or] and 5-[(2-benzyl-2,3-dihydrobenzopyran)-5-ylmethyl)thiazolidine-2,4-dione (or englitazone).

19. (Amended) A modified release composition according to claim [1] 18 being a delayed, pulsed or sustained release composition.

20. (Amended) A composition according to [ny one of] claim 16 [to 19], adapted to provide a method of treatment according to [any one] of claim[s] 1 [to 15].